2cureX was founded in 2006 with the vision of improving treatment efficiency of cancer patients. From the onset, 2cureX has been closely integrated with the cancer hospitals in the Copenhagen area. This has since been expanded to include hospitals in Germany and United Kingdom.
Furthermore, we have successfully lead multiple collaborations with both commercial and academic partners.
2cureX has since its inception raised over €7 million in both national and international grants and private investments.
2cureX has developed the IndiTreat™, which has been developed and tested in more than 900 patients with promising results. 2cureX has in October 2017 started a clinical trial using IndiTreat™ with stage IV colorectal cancer patients.
2cureX will offer IndiTreat™ to cancer hospitals and clinics as a service. 2cureX is establishing laboratory facilities for conducting IndiTreat™ testing in multiple European countries.